nach oben

CardioVascular and Interventional Radiology

Erschienen in:

21.12.2016 | Review

Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease

verfasst von: Shamar Young, Donna D’Souza, Siobhan Flanagan, Jafar Golzarian

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer is a common malignancy that most commonly metastasizes to the liver. There has been considerable effort in developing new treatment options for these patients. One method that has been developed for the treatment of colorectal metastases to the liver is irinotecan-loaded drug-eluting bead (DEBIRI) embolization. This article reviews the current literature on DEBIRI and discusses the state of current knowledge and possible areas of future investigation.

Welch JP, Donaldson GA. The clinical correlation of autopsy study of recurrent colorectal cancer. Ann Surg. 1979;189:496–502.CrossRefPubMedPubMedCentral

Silverberg E. Cancer statistics, 1977. CA Cancer J Clin. 1977;27:26–41.CrossRefPubMed

Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994;343:1405–10.CrossRefPubMed

Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19:59–71.CrossRefPubMed

Fong Y. Hepatic colorectal metastasis: current surgical therapy, selection criteria for hepatectomy, and role for adjuvant therapy. Adv Surg. 2000;34:351–81.PubMed

Sinicrope A, Okamoto K, Kasi PM, Kawakami H. Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 2016;14(5):651–8.CrossRefPubMed

Ohhara Y, Fukuda N, Takeuchi S, et al. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol. 2016;8(9):642–55.CrossRefPubMedPubMedCentral

Gustavsson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14(1):1–10.CrossRefPubMed

Martin RC 2nd, Scoggins CR, Tomalty D, et al. Irinotecan drug-eluting beads in the treatment of chemo-naive unrespectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinectics and phase I trial. J Gastrointest Surg. 2012;16(8):1531–8.CrossRefPubMed

10.

Martinc RC 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121(20):3649–58.CrossRef

11.

Fiorentini G, Aliberti C, Sarti D, et al. Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World J Gastrintest Oncol. 2015;7(6):47–54.

12.

Akiwande O, Miller A, Hayes D, O’Hara R, Tomalty D, Martin RC. Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer. Anticancer Res. 2014;34(12):723–7245.

13.

Liu DM, Thakor AS, Baerlocher M, et al. A review of conventional and drug-eluting chemoembolization in the treatment of colorectal liver metastases: principles and proof. Future Oncol. 2015;11(9):1421–28.CrossRefPubMed

14.

Lencioni R, Aliberti C, de Baere T, et al. Transartrial treatment of colorectal cancer liver metastases with irinotecan-loaded drug-eluting beads: technical recommendations. J Vasc Interv Radiol. 2014;25(3):365–9.CrossRefPubMed

15.

Akinwande OK, Philips P, Duras P, Pluntke S, Scoggins C, Marin RC. Small versus large-sized drug-eluting beads (DEBIRI) for the treatment of hepatic colorectal metastases: a propensity score matching analysis. Cardiovasc Interv Radiol. 2015;38(2):361–71.CrossRef

16.

Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.PubMed

17.

Martin RC, Joshi J, Robbins K, Tomalty D, O’Hara R, Tatum C. Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol. 2009;2009:539795.CrossRefPubMedPubMedCentral

18.

Martin RC, Joshi J, Robbins K, et al. Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol. 2011;18(1):192–8.CrossRefPubMed

19.

Bhutiani N, Akinwande O, Martin RC 2nd, Efficacy and toxicity of hepatic intra-arterial drug-eluting (irinotecan) bead (DEBIRI) therapy in irinotecan-refractory unresectable colorectal liver metastases. World J Surg. 2016;40(5):1178–90.

20.

Akinwande O, Scoggins C, Martin RC. Early experience with 70–150 µm irinotecan drug-eluting beads (M1-DEBIRI) for the treatment of unresectable hepatic colorectal metastases. Anticancer Res. 2016;36(7):3413–8.PubMed

21.

Eichler K, Zangos S, Mack MG, et al. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). J Oncol. 2012;41(4):1213–20.

22.

Iezzi R, Marisico VA, Guerra A, et al. Trans-arterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a phase II single-center study. Cardiovasc Inerv Radiol. 2015;38(6):1523–31.CrossRef

23.

Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead^®, drug-luting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res. 2011;31(12):4581–7.PubMed

24.

Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res. 2013;33(5):2077–83.PubMed

25.

Abdalla EK, Bauer TW, Chun YS, D’Angelica M, Kooby DA, Jarnagin WR. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB(Oxford). 2013;15(2):119–30.

Titel: Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease
verfasst von: Shamar Young
Donna D’Souza
Siobhan Flanagan
Jafar Golzarian
Publikationsdatum: 21.12.2016
Verlag: Springer US
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 4/2017
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-016-1537-5

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Review of the Clinical Evidence for the Use of DEBIRI in the Treatment of Colorectal Metastatic Disease

Abstract

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Prostatic Artery Embolization as an Alternative to Indwelling Bladder Catheterization to Manage Benign Prostatic Hyperplasia in Poor Surgical Candidates

The IR Point of View: Action Cameras for IR Action

Percutaneous Ultrasound-Guided Carpal Tunnel Release: Study Upon Clinical Efficacy and Safety

The Results of Ultrasonography-Guided Percutaneous Radiofrequency Ablation in Hyperparathyroid Patients in Whom Surgery Is Not Feasible

Using a Motion Sensor-Equipped Smartphone to Facilitate CT-Guided Puncture

Regarding “Transarterial Embolization of Anomalous Systemic Arterial Supply to Normal Basal Segments of the Lung”

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie